These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 25000171)
1. A platform stratifying a sequestering agent and a pharmacological antagonist as a means to negate botulinum neurotoxicity. Harris TL; Lowery CA; Hixon MS; Janda KD ACS Chem Neurosci; 2014 Aug; 5(8):632-6. PubMed ID: 25000171 [TBL] [Abstract][Full Text] [Related]
2. Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin. Adler M; Macdonald DA; Sellin LC; Parker GW Toxicon; 1996 Feb; 34(2):237-49. PubMed ID: 8711757 [TBL] [Abstract][Full Text] [Related]
3. A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism. Simpson LL Infect Immun; 1986 Jun; 52(3):858-62. PubMed ID: 3011675 [TBL] [Abstract][Full Text] [Related]
4. Symptomatic treatment of botulism with a clinically approved small molecule. Vazquez-Cintron E; Machamer J; Ondeck C; Pagarigan K; Winner B; Bodner P; Kelly K; Pennington MR; McNutt P JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31996484 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction. Kauffman JA; Way JF; Siegel LS; Sellin LC Toxicol Appl Pharmacol; 1985 Jun; 79(2):211-7. PubMed ID: 2988154 [TBL] [Abstract][Full Text] [Related]
6. Effect of 3,4-diaminopyridine on the survival of mice injected with botulinum neurotoxin type A, B, E, or F. Siegel LS; Johnson-Winegar AD; Sellin LC Toxicol Appl Pharmacol; 1986 Jun; 84(2):255-63. PubMed ID: 3715874 [TBL] [Abstract][Full Text] [Related]
8. Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps. Adler M; Capacio B; Deshpande SS Toxicon; 2000 Oct; 38(10):1381-8. PubMed ID: 10758273 [TBL] [Abstract][Full Text] [Related]
9. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Adler M; Keller JE; Sheridan RE; Deshpande SS Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741 [TBL] [Abstract][Full Text] [Related]
11. Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Angaut-Petit D; Molgó J; Comella JX; Faille L; Tabti N Neuroscience; 1990; 37(3):799-808. PubMed ID: 1701041 [TBL] [Abstract][Full Text] [Related]
12. Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist. Tarr TB; Lacomis D; Reddel SW; Liang M; Valdomir G; Frasso M; Wipf P; Meriney SD J Physiol; 2014 Aug; 592(16):3687-96. PubMed ID: 25015919 [TBL] [Abstract][Full Text] [Related]
13. Aminoglycosides and 3,4-diaminopyridine on neuromuscular block caused by botulinum type A toxin. Molgó J; Lemeignan M; Thesleff S Muscle Nerve; 1987 Jun; 10(5):464-70. PubMed ID: 3497343 [TBL] [Abstract][Full Text] [Related]
14. Scorpion toxins for the reversal of BoNT-induced paralysis. Lowery CA; Adler M; Borrell A; Janda KD Bioorg Med Chem Lett; 2013 Dec; 23(24):6743-6. PubMed ID: 24252544 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine]. Yachachi Monfort A; Cortés Pastor F; de la Rubia Nieto A; Sánchez Garre MJ Farm Hosp; 2007; 31(4):254-6. PubMed ID: 18052623 [No Abstract] [Full Text] [Related]
17. Effect of 3,4-diaminopyridine on the gravity dependence of ocular drift in downbeat nystagmus. Helmchen C; Sprenger A; Rambold H; Sander T; Kömpf D; Straumann D Neurology; 2004 Aug; 63(4):752-3. PubMed ID: 15326263 [No Abstract] [Full Text] [Related]
18. Ineffectiveness of 3,4-diaminopyridine as a therapy for type C botulism. Siegel LS; Price JI Toxicon; 1987; 25(9):1015-8. PubMed ID: 3433299 [TBL] [Abstract][Full Text] [Related]
19. Acetylator Status Impacts Amifampridine Phosphate (Firdapse™) Pharmacokinetics and Exposure to a Greater Extent Than Renal Function. Haroldsen PE; Sisic Z; Datt J; Musson DG; Ingenito G Clin Ther; 2017 Jul; 39(7):1360-1370. PubMed ID: 28641995 [TBL] [Abstract][Full Text] [Related]
20. Investigations into small molecule non-peptidic inhibitors of the botulinum neurotoxins. Capková K; Salzameda NT; Janda KD Toxicon; 2009 Oct; 54(5):575-82. PubMed ID: 19327377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]